Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Matsubara · SciRah

Researcher profile · Semantic Scholar

N. Matsubara

Share profile

N. Matsubara — researcher profile on SciRah

h-index: 37
Works: 260
Citations: 9,855

Most-cited papers

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
T. Powles, T. Csőszi, M. Özgüroğlu, N. Matsubara +16 more
2021The Lancet Oncology497 citations Open access
Semantic Scholar
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
N. Agarwal, A. Azad, J. Carles, A. Fay +17 more
2023The Lancet388 citations Open access
Semantic Scholar
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Y. Loriot, N. Matsubara, Se Hoon Park, R. Huddart +14 more
2023New England Journal of Medicine229 citations
Semantic Scholar
Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate cancer: a randomised phase 3 trial
T. Powles, Kobe Yuen, S. Gillessen, E. Kadel +16 more
2022Nature Medicine218 citations Open access
Semantic Scholar
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma.
J. Rosenberg, T. Powles, G. Sonpavde, Y. Loriot +10 more
2023Annals of Oncology156 citations Open access
Semantic Scholar
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
K. Fizazi, A. Azad, N. Matsubara, J. Carles +17 more
2023Nature Medicine147 citations Open access
Semantic Scholar
Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
M. Hussain, C. Corcoran, Caroline Sibilla, K. Fizazi +21 more
2022Clinical Cancer Research97 citations Open access
Semantic Scholar
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
W. Kelly, D. Danila, Chia-Chi Lin, Jae-Lyun Lee +17 more
2023Cancer Discovery82 citations Open access
Semantic Scholar
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
J. Mateo, J. de Bono, K. Fizazi, Fred Saad +19 more
2023Journal of Clinical Oncology73 citations Open access
Semantic Scholar
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
N. Agarwal, A. Azad, J. Carles, A. Fay +16 more
2023Journal of Clinical Oncology46 citations
Semantic Scholar
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
Y. Loriot, N. Matsubara, S. Park, R. Huddart +11 more
2023Journal of Clinical Oncology44 citations
Semantic Scholar
Japanese clinical practice guidelines for prostate cancer 2023
Y. Kohjimoto, H. Uemura, M. Yoshida, S. Hinotsu +20 more
2024International journal of urology42 citations Open access
Semantic Scholar
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
N. Agarwal, Fred Saad, A. Azad, J. Mateo +7 more
2023Future Oncology42 citations Open access
Semantic Scholar
Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
N. Matsubara, J. Yonese, T. Kojima, H. Azuma +8 more
2022Cancer Medicine42 citations Open access
Semantic Scholar
A PHASE 1 STUDY OF ACAPATAMAB, A HALF-LIFE EXTENDED, PSMA-TARGETING BISPECIFIC T-CELL ENGAGER FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
T. Dorff, L. Horvath, K. Autio, A. Bernard-Tessier +24 more
2024Clinical Cancer Research37 citations Open access
Semantic Scholar
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
N. Matsubara, J. de Bono, D. Olmos, G. Procopio +17 more
2022Clinical Cancer Research35 citations Open access
Semantic Scholar
Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
D. Petrylak, R. Ratta, N. Matsubara, E. Korbenfeld +16 more
2023Journal of Clinical Oncology32 citations Open access
Semantic Scholar
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
G. Baciarello, M. Özgüroğlu, S. Mundle, G. Leitz +6 more
2021European Journal of Cancer30 citations Open access
Semantic Scholar
Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).
N. Agarwal, A. Azad, K. Fizazi, J. Mateo +7 more
2022Journal of Clinical Oncology29 citations
Semantic Scholar
Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
T. Doi, K. Shitara, T. Kojima, Y. Kuboki +8 more
2022Cancer Science29 citations Open access
Semantic Scholar
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
A. Thiery-Vuillemin, J. de Bono, M. Hussain, G. Roubaud +14 more
2022The Lancet Oncology25 citations Open access
Semantic Scholar
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
N. Matsubara, R. de Wit, A. Balar, A. Siefker-Radtke +17 more
2023European Urology24 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
S. Tamada, C. Kondoh, N. Matsubara, R. Mizuno +13 more
2021International Journal of Clinical Oncology23 citations Open access
Semantic Scholar
Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.
J. de Bono, N. Matsubara, N. Penel, N. Mehra +16 more
202122 citations
Semantic Scholar
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
G. Roubaud, M. Özgüroğlu, N. Penel, N. Matsubara +19 more
2022European Journal of Cancer21 citations Open access
Semantic Scholar
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
H. Nakajima, K. Harano, T. Nakai, S. Kusuhara +9 more
2022Breast20 citations Open access
Semantic Scholar
PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study
Y. Kuboki, T. Koyama, N. Matsubara, Y. Naito +11 more
2024Cancer Medicine19 citations Open access
Semantic Scholar
CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
N. Agarwal, A. Azad, J. Carles, N. Matsubara +16 more
2024Journal of Clinical Oncology19 citations Open access
Semantic Scholar
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
Y. Loriot, P. Grivas, R. de Wit, A. Balar +15 more
2022Journal of Clinical Oncology17 citations Open access
Semantic Scholar
Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001).
T. Powles, Evan Y. Yu, G. Iyer, M. Campbell +11 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.
N. Matsubara, J. de Bono, D. Olmos, G. Procopio +16 more
202116 citations
Semantic Scholar
Effects of ado-trastuzumab emtansine and fam-trastuzumab deruxtecan on metastatic breast cancer harboring HER2 amplification and the L755S mutation.
T. Mukohara, A. Hosono, S. Mimaki, Akiko Nakayama +10 more
2021The Oncologist14 citations Open access
Semantic Scholar
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
D. Petrylak, Y. Chia, Evan Y. Yu, T. Powles +16 more
2024Journal of Clinical Oncology13 citations Open access
Semantic Scholar
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
K. Fizazi, A. Azad, N. Matsubara, J. Carles +15 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
Hybrid double-spiral microfluidic chip for RBC-lysis-free enrichment of rare cells from whole blood.
K. Shirai, Guo-Feng Guan, M. Tan, Xiaoling Peng +8 more
2022Lab on a Chip13 citations
Semantic Scholar
1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.
T. Powles, T. Csőszi, M. Ozguroglu, N. Matsubara +16 more
202113 citations
Semantic Scholar
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project
Masaki Shiota, N. Matsubara, Taigo Kato, M. Eto +12 more
2024BJC Reports12 citations Open access
Semantic Scholar
Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects
T. Yap, D. Tan, A. Stathis, G. Shapiro +16 more
2022Cancer Research12 citations
Semantic Scholar
Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
T. Powles, J. Rosenberg, G. Sonpavde, Y. Loriot +8 more
202112 citations
Semantic Scholar
Dirty necrosis in renal cell carcinoma is associated with NETosis and systemic inflammation
Takashi Kuroe, R. Watanabe, R. Morisue, Saori Miyazaki +10 more
2022Cancer Medicine11 citations Open access
Semantic Scholar
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
M. S. van der Heijden, T. Powles, D. Petrylak, R. de Wit +21 more
2022Nature Communications11 citations Open access
Semantic Scholar
Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference
K. Fujita, Hiroyoshi Suzuki, Nobuyuki Hinata, Y. Miura +8 more
2021Translational Andrology and Urology11 citations Open access
Semantic Scholar
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
A. Fléchon, R. Morales-Barrera, T. Powles, A. Alva +27 more
2024Clinical Cancer Research10 citations Open access
Semantic Scholar
Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
G. Iyer, A. Siefker-Radtke, M. Milowsky, N. Shore +21 more
2023Cancer Research9 citations
Semantic Scholar
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
Y. Naito, Y. Kuboki, M. Ikeda, K. Harano +6 more
2021Investigational new drugs9 citations Open access
Semantic Scholar
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
N. Matsubara, Yuji Miura, Hiroyuki Nishiyama, R. Taoka +10 more
2024International Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
C. Funasaka, Y. Naito, S. Kusuhara, T. Nakao +11 more
2022Japanese Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.
A. Azad, K. Fizazi, N. Matsubara, F. Saad +15 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
D. Danila, D. Waterhouse, L. Appleman, D. Pook +11 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
R. de Wit, T. Powles, D. Castellano, A. Necchi +14 more
2022British Journal of Clinical Pharmacology6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Shore×13
Invite
N. Shore — researcher profile on SciRah
K. Fizazi×12
Invite
K. Fizazi — researcher profile on SciRah
T. Powles×11
Invite
T. Powles — researcher profile on SciRah
Y. Loriot×10
Invite
Y. Loriot — researcher profile on SciRah

×10

Invite

N. Agarwal — researcher profile on SciRah

Invite

J. Joung — researcher profile on SciRah

Invite

C. Poehlein — researcher profile on SciRah

Invite

D. Petrylak — researcher profile on SciRah

Invite

Jin-Yu Kang — researcher profile on SciRah

Invite

J. de Bono — researcher profile on SciRah

Invite

Y. Naito — researcher profile on SciRah

M. Özgüroğlu×5

Invite

M. Özgüroğlu — researcher profile on SciRah